ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 147 filers reported holding ASCENDIS PHARMA A/S in Q4 2019. The put-call ratio across all filers is 0.23 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $351,000 | +33.0% | 2,993 | +52.5% | 0.02% | +36.4% |
| Q4 2021 | $264,000 | -41.2% | 1,963 | -30.4% | 0.01% | -50.0% |
| Q3 2021 | $449,000 | +44.4% | 2,819 | +19.1% | 0.02% | +37.5% |
| Q2 2021 | $311,000 | +5.8% | 2,367 | +3.7% | 0.02% | -5.9% |
| Q1 2021 | $294,000 | -7.5% | 2,282 | +19.9% | 0.02% | -22.7% |
| Q4 2020 | $318,000 | -17.6% | 1,904 | -23.9% | 0.02% | -85.1% |
| Q3 2020 | $386,000 | +0.8% | 2,503 | -3.4% | 0.15% | +335.3% |
| Q2 2020 | $383,000 | +23.5% | 2,590 | -6.0% | 0.03% | +3.0% |
| Q1 2020 | $310,000 | -32.2% | 2,755 | -16.1% | 0.03% | -5.7% |
| Q4 2019 | $457,000 | – | 3,282 | – | 0.04% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management III, LLC | 133,691 | $13,805,000 | 36.44% |
| RA Capital Management | 7,567,900 | $781,462,000 | 16.67% |
| Q Global Advisors, LLC | 145,209 | $16,699,000 | 11.49% |
| BERYLSON CAPITAL PARTNERS, LLC | 51,000 | $5,266,000 | 8.70% |
| Spyglass Capital Management LLC | 949,915 | $98,088,000 | 6.94% |
| Paradigm Biocapital Advisors LP | 497,347 | $51,356,000 | 6.85% |
| Avoro Capital Advisors LLC | 2,850,000 | $294,291,000 | 5.44% |
| Deep Track Capital, LP | 1,000,000 | $103,260,000 | 4.73% |
| Finepoint Capital LP | 123,400 | $12,742,000 | 4.19% |
| Deep Track Capital, LP | 800,000 | $82,608,000 | 3.78% |